Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Therapy-related myelodysplastic syndrome (t-MDS) is often classified using schemes for de novo MDS.
• Limited data exist on the prognostic value of these classifications in t-MDS.

Purpose of the Study:

• To evaluate the World Health Organization (WHO) criteria for de novo MDS in t-MDS prognostication.
• To assess the prognostic importance of cytogenetic stratification and karyotypic complexity in t-MDS.

Main Methods:

• Analysis of 155 patients with therapy-related acute myeloid leukemia (t-AML)/t-MDS.
• Subclassification based on WHO criteria for de novo MDS.
• Assessment of International Prognostic Scoring System (IPSS) guidelines and karyotypic complexity.

Main Results:

• No survival differences were observed among WHO MDS subgroups or based on bone marrow blast percentage.
• Cytogenetic stratification via IPSS guidelines and karyotypic complexity showed significant survival differences.
• A borderline difference in median survival was noted between initial t-MDS and t-AML diagnoses.

Conclusions:

• Morphologic classification does not provide prognostic information in t-MDS, indicating a uniformly poor outcome.
• Cytogenetic factors are crucial for predicting survival in therapy-related myeloid malignancies.
• Further research may clarify the distinction between t-MDS and t-AML prognoses.